Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS
TL;DR
Quantum BioPharma's agreement to produce Lucid-MS could position it as a leader in MS treatment, offering a competitive edge in the biopharmaceutical market.
Quantum BioPharma's subsidiary has partnered with a CDMO to develop an oral formulation of Lucid-MS, advancing toward Phase 2 clinical trials for MS treatment.
Lucid-MS's potential to restore mobility in MS patients represents a significant step toward improving quality of life for those with neurodegenerative diseases.
Discover how Quantum BioPharma's Lucid-MS, a neuroprotective compound, could revolutionize MS treatment by reversing myelin degradation in preclinical models.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a pivotal development in its quest to address multiple sclerosis (MS) through its subsidiary, Huge Biopharma Australia Pty Ltd. The company has entered into an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS for its upcoming Phase 2 clinical trial. This trial aims to evaluate the efficacy of Lucid-MS in restoring mobility in individuals suffering from MS, a condition that affects millions worldwide.
Lucid-MS represents a breakthrough as a patented, first-in-class, non-immunomodulatory neuroprotective compound. Its potential lies in its demonstrated ability to prevent demyelination, a critical factor in the progression of MS and other neurodegenerative diseases. The agreement with the CDMO is a crucial milestone towards filing an Investigational New Drug (IND) application with the FDA for Lucid-21-302 in MS, marking a significant step in the drug's development pathway.
The implications of this development are profound for the MS community and the broader field of neurodegenerative disease treatment. With a decade of preclinical studies showing promising results, including the restoration of walking ability in animal models, Lucid-MS could offer a new hope for patients. The move to Phase 2 trials underscores Quantum BioPharma's commitment to advancing innovative treatments for challenging conditions.
For more information on Quantum BioPharma's groundbreaking work and its portfolio of innovative assets, visit https://ibn.fm/y8RRY. This development not only highlights the company's dedication to addressing unmet medical needs but also its strategic approach to leveraging partnerships to accelerate the delivery of potential therapies to the market.
Curated from InvestorBrandNetwork (IBN)
